UNRESECTABLE HEPATOCELLULAR CARCINOMA

This pilot study is testing a new strategy for patients with liver cancer that cannot be surgically removed. Researchers will combine immunotherapy (which uses the body's immune system) with highly focused radiation to try to shrink tumors. The goal is to make the cancer small en…

This study is testing the safety of combining two immunotherapy drugs (atezolizumab and bevacizumab) with a precise form of radiation therapy for advanced liver cancer that cannot be surgically removed. The goal is to see if this three-part approach can better control the cancer …

This study is testing a new combination treatment for advanced liver cancer that cannot be removed by surgery. Doctors take a patient's own immune cells, grow and train them in a lab to attack cancer, and then inject them directly into the tumor after radiation therapy. The goal …

This study is testing whether combining a cancer drug (regorafenib) with a targeted radiation treatment (Y-90 radioembolization) can better control advanced liver cancer that cannot be removed by surgery. It will enroll 30 adults who have not had prior drug treatment for their ca…

This study is testing a new combination treatment for liver cancer that cannot be removed by surgery. It combines a targeted radiation therapy delivered directly to the liver with two immunotherapy drugs and one targeted cancer drug. The main goals are to see if this four-part tr…

This study is testing a new drug called PF-08634404 to see if it is safe and effective for treating advanced liver cancer that cannot be removed by surgery. It will be given alone or combined with another drug (ipilimumab) to 138 adults who have not had other whole-body treatment…

This study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…

This study is for people with advanced liver cancer that cannot be removed by surgery and has continued to grow despite their first treatment. Researchers want to see if continuing one of the original drugs (atezolizumab) alongside a new type of drug (cabozantinib or lenvatinib) …

This study aims to understand which treatments work best for advanced liver cancer after patients have received initial immunotherapy combinations. Researchers will collect data from 300 adults who have already started their next treatment as part of their regular care. The study…